Is AOD-9604 Legal in Texas? How to Access It Legally

What Exactly Is AOD-9604?

AOD-9604 is a synthetic peptide fragment derived from amino acids 176 to 191 of the human growth hormone (hGH) sequence. Researchers designed it to retain the lipolytic (fat-burning) properties of hGH while removing the insulin-like, diabetogenic effects of the full molecule. The fragment carries the C-terminal tail of hGH and stimulates fat breakdown through beta-3 adrenergic receptor pathways rather than via IGF-1 elevation.

Origin and Early Research

Metabolic Pharmaceuticals Ltd. In Australia conducted the bulk of clinical research on AOD-9604 between 2001 and 2007. Phase 2a and 2b randomized controlled trials enrolled obese adults and tested oral and subcutaneous forms. The most-cited Phase 2b trial (n=300, 24 weeks) found that subcutaneous AOD-9604 at 1 mg/day produced statistically significant fat mass reduction compared with placebo, though the effect size was modest [1]. No Phase 3 trial was ever initiated, and Metabolic Pharmaceuticals did not file a New Drug Application (NDA) with the FDA.

Why It Never Reached Approval

Without a completed Phase 3 program and an accepted NDA, AOD-9604 has no FDA-approved indication. The FDA granted it GRAS (Generally Recognized as Safe) status as a food ingredient in 2014, but that designation applies to the ingredient in food products only. It does not constitute drug approval, and it does not authorize any injectable or prescription use [2].

Federal Legal Status of AOD-9604

AOD-9604 is not a controlled substance under the Controlled Substances Act (CSA). The DEA's current scheduling lists contain no entry for AOD-9604 or its synonym "fragment 176-191." That single fact often leads people to assume the peptide is freely legal to buy or sell. The situation is more complicated.

The FDA's Bulk Compounding Substance Lists

The FDA regulates what bulk drug substances compounding pharmacies may use. Under the Federal Food, Drug, and Cosmetic Act (FDCA), Section 503A governs patient-specific (retail) compounding and Section 503B governs outsourcing facilities that compound in larger batches [3].

The FDA maintains three categories for bulk substances:

• Category 1: Nominated substances under active evaluation for inclusion on the 503B list.
• Category 2: Substances the FDA has determined should NOT be used in 503B compounding (often because they lack clinical evidence of safety or effectiveness at the compounded dose).
• Category 3: Substances still being reviewed with no final determination.

AOD-9604 appears on the FDA's Category 2 list for 503B outsourcing facilities, meaning large-scale outsourcing facilities (hospital suppliers, etc.) may not compound it [4]. The 503A list for patient-specific compounding pharmacies has separate, less-finalized guidance, and AOD-9604 has not been formally prohibited for 503A use at the time of this article's last review. This distinction matters. A 503A pharmacy filling an individual prescription from a licensed Texas physician is operating under different federal authority than a 503B outsourcing facility.

The "Research Chemical" Gray Area

Some vendors sell AOD-9604 labeled "for research use only" or "not for human use." These labels do not make the product legal for human administration. Under the FDCA, introducing an unapproved new drug into interstate commerce for human use is illegal regardless of the label. Purchasing injectable peptides from unregulated online sources exposes patients to unknown purity, sterility failures, and bacterial contamination. A 2022 analysis of "research peptide" products found that fewer than 50% met label-claimed concentration within a 10% margin [5].

Texas-Specific Legal Framework

Texas does not have a separate statute that explicitly legalizes or bans AOD-9604. State law operates on top of federal law; it does not replace it. The two agencies that govern legal AOD-9604 use in Texas are the Texas State Board of Pharmacy (TSBP) and the Texas Medical Board (TMB).

Texas State Board of Pharmacy Rules

The TSBP licenses and regulates pharmacies under Texas Occupations Code Chapter 558 and Texas Administrative Code Title 22. Texas compounding pharmacies that operate as 503A facilities must comply with USP <797> sterile compounding standards and may only compound drugs that are not commercially available in an FDA-approved form. Because no FDA-approved AOD-9604 drug product exists, a 503A pharmacy in Texas may compound it from a bulk active pharmaceutical ingredient (API) provided that API is sourced from an FDA-registered facility and the pharmacy holds a valid sterile compounding license [6].

The TSBP has not issued a specific advisory, guidance letter, or rule singling out AOD-9604 for prohibition as of January 2025.

Texas Medical Board and Prescribing Authority

Under the Texas Medical Practice Act (Texas Occupations Code Chapter 151), a licensed Texas physician has broad authority to prescribe any legal substance for a patient when it is medically indicated and within the standard of care. AOD-9604 prescribed for weight management in an obese patient (BMI >30, or BMI >27 with a weight-related comorbidity) can be justified under the physician's professional judgment, provided the physician documents the clinical rationale, obtains informed consent, and maintains appropriate follow-up.

The TMB's standard-of-care framework does not require FDA approval of a compound for a physician to prescribe it. Off-label and compounded prescribing is a well-established practice in American medicine, explicitly acknowledged by the FDA [7]. What the TMB does require is that the physician practice within accepted medical norms, not abandon standard proven therapies without reason, and monitor the patient's response.

What a Valid Texas AOD-9604 Prescription Looks Like

A legally compliant AOD-9604 prescription in Texas must include:

• A valid prescriber-patient relationship (the physician must evaluate the patient, in-person or via a legitimate telemedicine encounter compliant with Texas telemedicine law)
• A specific compounding pharmacy name (the prescription flows to one pharmacy, not to the patient to "fill anywhere")
• A defined dose, route, frequency, and quantity
• A refill limit consistent with clinical monitoring

Prescriptions written only to support a sale or issued without a clinical evaluation violate the Texas Medical Practice Act and federal law.

How to Get AOD-9604 in Texas: A Step-by-Step Path

The following framework describes the only legally defensible path to AOD-9604 in Texas as of January 2025.

Step 1: Establish Care With a Licensed Texas Physician

The physician must be licensed by the TMB and must conduct a clinical evaluation. For AOD-9604, a standard workup includes BMI measurement, fasting metabolic panel, thyroid function tests, and a review of prior weight-loss interventions. Telehealth is permitted in Texas under Senate Bill 1107 (2017) and subsequent TMB rules, provided the prescriber holds a Texas license and uses real-time audio-video communication for the initial encounter.

Step 2: Confirm You Meet Clinical Criteria

No consensus guideline currently recommends AOD-9604 as a first-line weight-loss agent. The Endocrine Society's 2015 obesity pharmacotherapy guidelines prioritize FDA-approved agents (orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, and now semaglutide) [8]. A physician prescribing AOD-9604 would typically reserve it for patients who have tried or cannot tolerate approved medications, or use it as an adjunct. Patients who qualify for semaglutide (Wegovy) under FDA approval, for example, should discuss that option first, given the substantially larger evidence base: the STEP-1 trial (n=1,961) showed semaglutide 2.4 mg produced 14.9% mean body weight reduction over 68 weeks versus 2.4% with placebo (P<0.001) [9].

Step 3: Receive a Prescription and Choose a Licensed 503A Pharmacy

Once the physician determines AOD-9604 is appropriate, they write a prescription to a specific Texas-licensed 503A compounding pharmacy. Reputable pharmacies will hold PCAB (Pharmacy Compounding Accreditation Board) accreditation, will source API from FDA-registered suppliers, and will provide a Certificate of Analysis (CoA) for each batch. Patients should ask for the CoA before injecting any compounded peptide.

Step 4: Follow Up and Monitor

AOD-9604 does not have established monitoring parameters in the way FDA-approved drugs do. Prudent follow-up includes monthly body composition assessment, liver function tests at baseline and 12 weeks, and blood pressure monitoring. Any adverse reaction should be reported through the FDA's MedWatch system.

Safety Profile and Known Risks

Phase 2 trials reported that AOD-9604 was generally well-tolerated in oral and subcutaneous forms. Adverse events in the Phase 2b trial were similar between active and placebo groups and included injection-site reactions, mild headache, and transient nausea [1]. No clinically significant changes in blood glucose, insulin, or IGF-1 were observed at therapeutic doses, which is the pharmacological feature that distinguishes it from full-length hGH.

What the Evidence Does Not Show

The Phase 2 data do not establish long-term cardiovascular safety, effects on bone density, or outcomes beyond 24 weeks. No trial has compared AOD-9604 head-to-head against any FDA-approved weight-loss drug. The FDA's Center for Drug Evaluation and Research has not reviewed an NDA for AOD-9604, meaning no agency has independently verified the original manufacturer's trial data.

The Endocrine Society's position, stated in its 2021 update on growth hormone and peptide therapies, is that "evidence is insufficient to recommend growth hormone secretagogues or growth hormone fragment peptides for body composition or weight management outside of a clinical trial setting" [10].

Contamination Risks From Non-Pharmacy Sources

Patients who bypass the physician-pharmacy pathway and purchase AOD-9604 from online research-peptide vendors take on substantial contamination risk. A 2018 study published in JAMA Internal Medicine found that a meaningful proportion of compounded and research-chemical injectables tested positive for microbial contamination or contained less than 90% of the labeled active ingredient [11]. Sterile compounding under USP <797> at a licensed pharmacy is the only production standard that addresses these risks systematically.

AOD-9604 vs. FDA-Approved Alternatives in Texas

Texas patients seeking physician-supervised weight loss have access to the full range of FDA-approved therapies. The table below places AOD-9604 in context.

| Agent | FDA Approval | Evidence Base | Availability in Texas | |---|---|---|---| | Semaglutide (Wegovy) | Yes (2021) | STEP-1 to STEP-4 program, n > 4,500 | Commercial pharmacy with prescription | | Tirzepatide (Zepbound) | Yes (2023) | SURMOUNT-1, n=2,539; 20.9% weight loss | Commercial pharmacy with prescription | | Phentermine-topiramate (Qsymia) | Yes (2012) | CONQUER trial, n=2,487 | Commercial pharmacy with prescription | | Naltrexone-bupropion (Contrave) | Yes (2014) | COR-I trial, n=1,742 | Commercial pharmacy with prescription | | AOD-9604 (compounded) | No | Phase 2b only, n=300, 24 weeks | 503A compounding pharmacy with Rx |

Physicians at HealthRX evaluate each patient's history, comorbidities, and prior treatment responses before recommending any peptide or GLP-1 therapy.

Telemedicine and AOD-9604 in Texas

Texas telemedicine law permits a physician to establish a valid prescriber-patient relationship via synchronous audio-video communication. The Texas Medical Board clarified in its 2020 amended rules that telemedicine encounters meet the standard of care for most non-emergency prescribing, including compounded medications, provided the physician reviews relevant medical history and diagnostic data [12].

This means a Texas resident does not need to travel to a clinic to access AOD-9604 lawfully. A board-certified physician practicing via a licensed telehealth platform can evaluate the patient, review labs, and send a prescription to a TSBP-licensed 503A pharmacy that ships to the patient's Texas address.

One important boundary: the pharmacy must hold a Texas license or a non-resident pharmacy permit from the TSBP. Receiving a shipment from an out-of-state pharmacy that does not hold a Texas permit may violate state pharmacy law, regardless of the prescription's validity.

Enforcement Reality and Risk Tolerance

The FDA has, since 2021, increased enforcement actions targeting compounding pharmacies that compound Category 2 bulk substances for 503B distribution, and it has sent warning letters to pharmacies advertising peptides directly to consumers without valid prescriptions [4]. Texas has not issued state-level enforcement actions specifically targeting AOD-9604 prescribing as of the date of this article.

The practical risk for a patient who obtains AOD-9604 through the 503A/physician pathway is low. The legal and health risk for a patient who purchases it from an unregulated online vendor is substantially higher, encompassing potential FDCA violations for receiving a misbranded or adulterated drug in interstate commerce, and direct health risk from contaminated product.